Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression Leticia Medina-GundrumCesario CernaElzbieta Izbicka OriginalPaper Pages: 3 - 9
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions Ephraim P. LanskyWenguo JiangMoray J. Campbell OriginalPaper Pages: 11 - 20
Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123 Ming-Sing SiBruce A. ReitzDominic C. Borie OriginalPaper Pages: 21 - 29
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor John L. MarshallHedy KindlerMark J. Ratain OriginalPaper Pages: 31 - 37
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects Aimee K. BenceEric B. AndersonVal R. Adams OriginalPaper Pages: 39 - 49
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98) Georg A. BjarnasonDanielle CharpentierLesley Seymour OriginalPaper Pages: 51 - 56
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors Basil F. El-RayesDina IbrahimPhilip A. Philip OriginalPaper Pages: 57 - 62
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin R. GoelE. ChouinardL. Seymour OriginalPaper Pages: 63 - 71
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status Gee-Chen ChangKun-Chieh ChenJeng-Yuan Hsu OriginalPaper Pages: 73 - 77
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC) Tahir LatifLaura WoodDavid Peereboom OriginalPaper Pages: 79 - 84
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer Francesco CaponigroPax WillemseJantien Wanders OriginalPaper Pages: 85 - 89